Conditions: Major Depressive Disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 586
Healthy volunteers: no

Brief summary:
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in patients with major depressive disorder.

Detailed description:

Arms:
arm 1: Fixed dose arm 2: Titration dose arm 3: Placebo

Interventions: intervention 1: Aripiprazole (Fixed dose) intervention 2: Aripiprazole (Titrated dose) intervention 3: Placebo
Intervention descriptions: intervention 1: administered orally once daily, 3 mg daily, 6 weeks intervention 2: administered orally once daily, 3 to 15 mg daily, 6 weeks intervention 3: administered orally once daily, 6 weeks

Protocol document: